Implications of Antiretroviral Drug Use for HIV Prevention Interventions on Elevated Risk for STIs: Critical Questions for Implementation Effectiveness and Evaluation
Implications of Antiretroviral Drug Use for HIV Prevention Interventions on Elevated Risk for STIs Part I: Problem Statement PrEP is a biomedical interventional strategy in which healthy people routinely take one or more antiretroviral (ARV) drugs to reduce their risk of getting HIV through sex. Three RCTs have studied the effects of PrEP on the acquisition of HIV infection***. The first landmark study, the Pre-exposure Prophylaxis Initiative (iPrEX) looked at the effect of daily use of tenofovir-emtricitabine in 2499 MSM from six countries (Peru, Ecuador, South Africa, Brazil, Thailand, and the USA) and was published in 2010. The PRe-exposure Option for reducing HIV in the UK, immediate or Deferred (PROUD) trial enrolled 544 MSM in the UK and randomly assigned them to immediate or a 1 year delayed start of daily oral tenofoviremtricitabine. In the Intervention Préventive de l’Exposition aux Risques avec et pour les Gays (Ipergay) trial, ** ** MSM were randomly assigned to ...